Navigation Links
Cardica Updates Enrollment Progress In European Clinical Trial
Date:2/27/2013

REDWOOD CITY, Calif., Feb. 27, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced that 109 patients have been enrolled in the company's European clinical trial designed to evaluate the safety of its MicroCutter XCHANGE™ 30 cutting/stapling device in a variety of surgical procedures. Cardica plans to complete enrollment of 160 patients for the European clinical trial in the second calendar quarter of 2013.

"We are making progress with the MicroCutter XCHANGE 30 in Europe," said Bernard A. Hausen , M.D., Ph.D., president and chief executive officer of Cardica. "In the last four weeks, we have enrolled an additional 19 patients in our clinical trial, with more scheduled in the days ahead. And, we continue to gain valuable feedback from European surgeons deploying the device in a variety of procedures, to prepare the device for broader distribution in the near future. To date the MicroCutter XCHANGE 30 device has been used in over 280 procedures and deployed more than 800 times."

About Cardica 

Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 44,100 units throughout the world. In addition, Cardica is developing the Cardica® MicroCutter XCHANGE™ 30, a cartridge-based microcutter device with a five-millimeter shaft diameter, and the Cardica® MicroCutter XPRESS™ 30, a true multi-fire laparoscopic stapling device. Both MicroCutter devices are designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 30 and XPRESS 30 products require 510(k) review and are not yet commercially available in the U.S. 

Forward-Looking Statements

The statement in this press release regarding Cardica's plans to complete enrollment in the European clinical trial in the second quarter of calendar year 2013,  is a "forward-looking statement." There are a number of important factors that could cause Cardica's results to differ materially from those indicated by this forward-looking statement, including:  that the XCHANGE 30 may face development, regulatory and manufacturing risks; that surgeons may not use the XCHANGE 30 correctly, which could cause unfavorable results that may impair the acceptance of the XCHANGE 30 by other surgeons or otherwise delay completion of enrollment; and that Cardica may not have sufficient funds to complete enrollment in the clinical trial, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Current Report on Form 10-Q for the quarter ended December 31, 2012. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Announces Fiscal 2012 Third Quarter Financial Results
2. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
3. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
4. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
7. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
8. Cardica Announces Fiscal 2013 Second Quarter Financial Results
9. Neuralstem Updates ALS Stem Cell Trial Progress
10. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
11. TPI Provides Further Updates on its GMOL Flagship Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its ... health care service center company based in ... relationship management programs for leading pharmaceutical manufacturers and health ... WRB will join Envoy Health Management, LLC , ... biotech firms, and other service companies. Together, WRB and ...
(Date:5/4/2017)... May 4, 2017  A recent study published ... Ultraviolet-C light as a means of disinfection ... to reduce bioburden on anesthesia workstations. In the ... high-touch, complex medical equipment surfaces contaminated with three ... "This study further validates the body of ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a smart ... in an infographic on the current state of anxiety in support of National Mental ... was conducted in April 2017 and benchmarked general anxiety levels as well as identified ...
(Date:5/22/2017)... NC (PRWEB) , ... May 22, 2017 , ... ... Matthews Periodontics, is now welcoming new patients with periodontal plastic surgery treatments, including ... from a general dentist. Dr. Green provides these esthetic and functional procedures to ...
(Date:5/22/2017)... ... May 22, 2017 , ... Galena, Alaska, has a population of less ... headlines when it was targeted to build a nuclear plant by the TOSHIBA Corporation. ... manager Marvin L. Yoder describes the journey to get power to his small town, ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... Chris Cornell, 52, was found dead on ... why one of the most respected lead singers in the rock industry would take his ... of mental illness. FindaTopDoc investigates how mental illness played a role in the death of ...
(Date:5/21/2017)... PARK, FL (PRWEB) , ... May 20, 2017 , ... ... sell it, find it, review it, and share its attributes like never before. More ... dispensary directory to connect cannabis enthusiasts to stores, strains, products – and for the ...
Breaking Medicine News(10 mins):